KEKatharina Egger-Heidrich

Katharina Egger-Heidrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katharina Egger-Heidrich has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

    by Pauline Rocke, Lena Tandetzky, Daniel Wolff, Katharina Egger‐Heidrich, Daniela Heidenreich, Kerstin Schaefer‐Eckart, Eva Wagner‐Drouet, Jochen J. Frietsch, Andreas Hochhaus, Inken Hilgendorf

    Summary: Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until day 100 after alloHSCT were enrolled. Median patient age was 29.3 years. Chronic graft‐versus‐host disease (cGvHD) occurred in 40.2%. Comorbidities were captured at days 100, 180, 365 and 910 by applying the post‐transplant multimorbidity index (PTMI). Considering all time points, 12.5%–23.5% of patients had no comorbidity, while 39.2%–49.5% had 1–3, 26.3%–33.0% had 4–6 and 5.7%–8.4% had >6 PTMI‐defined comorbidities respectively. The most prevalent PTMI‐based comorbidities were iron overload, hypogonadism, arterial hypertension, infections, hepatic dysfunction and osteopenia/osteoporosis. However, the spectrum of PTMI‐recorded comorbidities and those concurrently self‐reported by patients differed substantially. Factors linked to a higher PTMI were total body irradiation and active cGvHD. Investigating single PTMI‐defined comorbidities, we found significant associations of osteopenia/osteoporosis with cGvHD, ongoing immunosuppression and hypogonadism, which was more common among female survivors. These results provide a detailed analysis of the occurrence of a vast spectrum of PTMI‐defined comorbidities in YA after alloHSCT.

  • Open Access

    Survival Trends in Young Adults With Acute Leukaemia After AHSCT in Germany: Comparisons With Younger and Older Patients

    by Jochen J. Frietsch, Sarah Flossdorf, Ashrafossadat Ahmadian, Rita Beier, Claudia Schuh, Thomas Schroeder, Igor-Wolfgang Blau, Matthias Stelljes, Nicolaus Kröger, Katharina Egger-Heidrich, et al.

  • Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology

    by Sibylle C Mellinghoff, Blasius Liss, Jannik Stemler, Verena Petzer, Katharina Egger-Heidrich, Malte B Monin, Maximilian Christopeit, Nicola Giesen, Andrea Keppler-Hafkemeyer, Tessa Hattenhauer, et al.


  • Open Access

    Steady‐state mobilization with on‐demand plerixafor after CD38 antibody‐based induction in multiple myeloma patients

    by Maximilian Alexander Röhnert, Anna Seifert, Karolin Trautmann‐Grill, Christoph Röllig, Kristin Zimmer, Katharina Egger‐Heidrich, Marius Bill, Lisa Heberling, Freya Schulze, Matthias Blechschmidt, et al.

    Background: High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody‐based quadruplet induction regimens such as daratumumab‐VTd (Dara‐VTd) has raised concerns regarding impaired stem cell mobilization. Study Design and Methods: We conducted a retrospective single‐center analysis comparing steady‐state stem cell mobilization after Dara‐VTd versus bortezomib–cyclophosphamide–dexamethasone (VCd) induction. Mobilization kinetics, plerixafor use, and CD34 + collection outcomes were evaluated. CD34 + counts prior to first apheresis were adjusted for plerixafor use (adjCD34 + ). Multivariate logistic regression was performed to identify predictors of mobilization success. Results: Among 153 patients, 85 received Dara‐VTd and 68 received VCd. Despite significantly deeper responses after Dara‐VTd (≥VGPR 81% vs. 42%; p < .01), these patients showed lower adjCD34 + counts prior to first apheresis (16 vs. 50/μL; p < .01) and required plerixafor more frequently (64% vs. 15%; p < .01). Nevertheless, cumulative CD34 + yields were comparable between Dara‐VTd and VCd (6.4 vs. 6.0 × 10 6 CD34 + cells/kg; p = .15), and target yields were achieved in the majority of patients proceeding to apheresis (90% vs. 94%). Dara‐VTd induction, prior radiation, and high tumor burden were identified as independent negative predictors of mobilization success. Discussion: Although Dara‐VTd induction is associated with impaired mobilization kinetics, successful steady‐state mobilization remains feasible. On‐demand plerixafor use overcomes mobilization deficits, supporting this approach in patients receiving CD38‐based quadruplet induction therapy. Furthermore, follow‐up analysis of stem cell graft utilization demonstrates a high proportion of collected but unused stem cell grafts in both cohorts.


  • Top Cited Papers
    Open Access

    Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

    by Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva Maria Wagner-Drouet, Lutz P Mueller, Christoph Schmid, Stefan W Krause, Wolfgang Andreas Bethge, Edgar Jost, Uwe Platzbecker, et al.

    Attempting to induce a complete remission before allogeneic hematopoietic cell transplant (alloHCT) is current practice in patients with acute myeloid leukemia (AML). However, benefit of remission induction strategy (RIST) before alloHCT has never been proven in a prospective trial. Potent conditioning regimens exist that allow for successful alloHCT in patients with active AML. Therefore, the ASAP trial was conducted to test RIST by salvage chemotherapy before alloHCT against immediate transplant after intensified conditioning. In total, 281 patients with AML with poor response after first induction or untreated first relapse were randomized 1:1 to RIST with high-dose cytarabine plus mitoxantrone vs immediate alloHCT with sequential conditioning after nonintensive disease control (DisC) measures, preferentially watchful waiting only. Overall survival at 5 years from randomization analyzed according to intention-to-treat was 46.1% for DisC vs 47.5% for RIST (P = .82). In multivariable Cox regression analysis, genetic AML risk according to European LeukemiaNet criteria (P < .0001), age (P = .001), and comorbidities (P = .046) predicted survival, but not treatment arm (hazard ratio, 1.08 for DisC vs RIST; P = .67). In conclusion, long-term follow-up of the ASAP trial showed no survival advantage for standard salvage chemotherapy before alloHCT as opposed to immediate alloHCT. The trial results question the general concept of RIST with intensive standard salvage therapy before alloHCT for all patients, because immediate alloHCT may reduce time in hospital and health care expenses. Novel bridging therapies that are well tolerated, and posttransplant maintenance with targeted drugs are urgently warranted, especially for adverse-risk AML, to improve outcomes after alloHCT. This trial was registered at www.ClinicalTrials.gov as #NCT02461537.


  • Open Access

    Long-term surveillance recommendations for young adult cancer survivors

    by Katharina Egger-Heidrich, Franziska Wolters, Mareike Frick, Teresa Halbsguth, Theresa Müller, Hannah Woopen, Kristin Tausche, Diana Richter, Judith Gebauer


  • Open Access

    Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland

    by Alexander Denk, Matthias Alexander Fante, Silke Heidenreich, Hildegard T. Greinix, Eva-Maria Wagner Drouet, Katharina Egger-Heidrich, Julia Marx, Darina Kodzhabasheva, William Krüger, Gesine Bug, et al.


  • Open Access

    Paternal Split‐Liver Transplantation Followed by Haploidentical Hematopoietic Cell Transplantation in an Adult Patient With Protoporphyria‐Induced Liver Failure

    by Ulrich Stölzel, Lasse Jost, Daniel Seehofer, Katharina Egger‐Heidrich, Uwe Scheuermann, Kristina Hölig, Thomas Stauch, Desiree Kunadt, Detlef Schuppan, Johannes Schetelig, et al.

    Introduction: Erythropoietic Protoporphyria (EPP) caused skin light sensitivity and liver cirrhosis in a 35‐year‐old patient who subsequently developed liver‐failure.Methods: In absence of a human leukocyte antigens (HLA)‐matched‐unrelated donor, the father consented in donating for split liver transplantation (SLT) and allogeneic hematopoietic cell transplantation (HCT).Results: After bridging therapy and successful SLT a first paternal HCT resulted in graft failure. For a second haploidentical HCT a different regimen was applied leading to engraftment while protoporphyrin (PP) blood‐levels decreased to normal and skin light sensitivity skin disappeared, leading to complete remission in an immunosuppressive‐free patient.Conclusion: Haploidentical transplantation is a feasible treatment approach in EPP‐patients.Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission


  • Open Access

    Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

    by Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler, Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, et al.

    Background: The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutatedIDH1/2has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first complete remission (CR1) undergoing alloHCT or conventional chemo-consolidation and investigated outcome in respect toIDH1/2mutational subgroups (IDH1R132C, R132H and IDH2 R140Q, R172K).Methods: Genomic DNA was extracted from bone marrow or peripheral blood samples at diagnosis and analyzed forIDHmutations with denaturing high-performance liquid chromatography, Sanger sequencing and targeted myeloid panel next-generation sequencing, respectively. Statistical as-treated analyses were performed using R and standard statistical methods (Kruskal–Wallis test for continuous variables, Chi-square test for categorical variables, Cox regression for univariate and multivariable models), incorporating alloHCT as a time-dependent covariate.Results: Among 3234 patients achieving CR1, 7.8% harboredIDH1mutations (36% R132C and 47% R132H) and 10.9% carriedIDH2mutations (77% R140Q and 19% R172K). 852 patients underwent alloHCT in CR1. Within the alloHCT group, 6.2% had anIDH1mutation (43.4% R132C and 41.4% R132H) and 10% were characterized by anIDH2mutation (71.8% R140Q and 24.7% R172K). Variants IDH1 R132C and IDH2 R172K showed a significant benefit from alloHCT for OS (p = .017 andp = .049) and RFS (HR = 0.42,p = .048 andp = .009) compared with chemotherapy only. AlloHCT in IDH2 R140Q mutated AML resulted in longer RFS (HR = 0.4,p = .002).Conclusion: In this large as-treated analysis, we showed that alloHCT is able to overcome the negative prognostic impact of certainIDHmutational subclasses in first-line consolidation treatment and could pending prognostic validation, provide prognostic value for AML risk stratification and therapeutic decision making.